Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab + Tuvonralimab + GEMOX for unresectable or metastatic biliary tract malignancies
ChiCTR2500109695Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Bengbu Medical University
- Start
- Sep 2025
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of iparomlimab, tuvonralimab, gemcitabine and oxaliplatin in biliary cancer, sponsored by First Affiliated Hospital of Bengbu Medical University. Primary endpoint: Progression-free survival. Started Sep 2025; status: recruiting.
02
Drugs
iparomlimabtuvonralimabgemcitabineoxaliplatin
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2500109695.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109695.